Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Immune Dysfunction in Allergic Asthma

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Mark Schuyler, University of New Mexico
ClinicalTrials.gov Identifier:
NCT00189228
First received: September 10, 2005
Last updated: January 18, 2013
Last verified: January 2013

September 10, 2005
January 18, 2013
September 2005
June 2008   (final data collection date for primary outcome measure)
anti-KLH antibody [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Asthma and control patients are immunized with KLH
Not Provided
Complete list of historical versions of study NCT00189228 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Immune Dysfunction in Allergic Asthma
Not a Drug Trial. We Are Using Anti-IgE to Examine the Role of Pulmonary Mast Cells in Asthma

We are using anti-IgE to investigate the role of pulmonary mast cells in asthma.

Subjects with mild allergic asthma are examined before, immediately after and 2 months after a course of treatment with anti-IgE. The following are examined: Allergen skin tests, allergen induced asthma, peripheral blood basophils, pulmonary bronchial mucosal mast cells.

Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Asthma
Drug: Xolair
Patients are administered Xolair
Other Name: Xolair
Experimental: xolair
This is not a drug study examining differences of therapeutic outcomes. It uses Xolair as an intervention that might change the outcome of immunization.
Intervention: Drug: Xolair
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
18
June 2008
June 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

Mild asthma, adults -

Exclusion Criteria:

children. on inhaled or systemic steroids

-

Both
18 Years to 45 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00189228
UNMSCOR, R01HL044253
Yes
Mark Schuyler, University of New Mexico
University of New Mexico
National Heart, Lung, and Blood Institute (NHLBI)
Study Director: Mark Schuyler, MD UNM HSC
University of New Mexico
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP